Vaccination of Diffuse Large B- Cell Lymphoma Patients with Antigen-Primed Dendritic Cells

Dendritic cells (dcs) are professional antigen presenting cells that have a potential role in the initiating of immune responses. the cell vaccination is a new strategy in treatment of infectious diseases and cancers. in this study, we have generated monocyte-derived dendritic cells of lymphoma patient's peripheral blood mononuclear cells then; these cells were used as vaccine in lymphoma patients. we generated dendritic cell vaccine from lymphoma patient's blood monocytes with human interleukin-4, granulocyte monocyte colony stimulating factor and then, antigen–primed dcs were administrated subcutaneously close to the inguinal lymph nodes after maturation of dendritic cells. after 7 days, we analyzed immune response in lymphoma patients with determining of ldh, beta 2 microglobulin, cd4+t cell percent, cd8+ tcell percent and tumor size before and after vaccination. furthermore, phenotypic and functional analysis of dendritic cells was performed using anti cd83-fitc monoclonal antibodies. before vaccination, the mean ± sd of ldh was 530.62±140.65 but after vaccination it was 459±109.45 that significantly different between experimental groups (p=0.002). in addition, the cd8+ t cells percentage significantly different between two groups (p=0.002). we concluded that the use of dendritic cell probably is one of the suitable noninvasive treatments for lymphoma patients that they have not response to chemical drugs.